Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Summary

This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Timeline

Start

2024-05-14

Primary completion

2026-02-13

Completion

2026-02-13

Outcome

Outcome not reported

Stopped (Business): “Trial terminated due to a business decision, not based on any safety concerns.”

Drugs

Indications